The Latest Cardiac and Vascular News
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Results Will Be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions 2020 […]
‘Control Cholesterol’ to Support the NHS in Delivering on Long-Term Plan Ambitions and Improve Health Outcomes for Patients in the North West Coast of England Quality Management Approach Aims to Help Predict and Prevent Heart Attacks and Strokes For More […]
Repatha (Evolocumab) Late-Breaking Data Showcase First Phase 3 Study of a PCSK9 Inhibitor in Pediatric Heterozygous Familial Hypercholesterolemia New Data Highlight Gaps in Treating High LDL-C to Clinical Treatment Guidelines in a Large Cohort of European, High-Risk CVD Patients THOUSAND […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical […]
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast […]
Amgen K.K. Will Focus on Bringing Amgen’s Full Global Pipeline to Japanese Patients THOUSAND OAKS, Calif., March 31, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. […]
Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV THOUSAND OAKS, Calif., March 28, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive results […]
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes Topline Results Expected in Q4 2020 THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 26, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) […]
Additional FOURIER Analysis Shows Lowering LDL-C With Repatha Did Not Impair Patient-Reported Cognition THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ — Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who […]
New Registry, cvMOBIUS, Will Assess Lipid Therapies and Five-Year Cardiovascular Outcomes in 8,500 High-Risk Patients With a Recent Atherosclerotic Cardiovascular Disease Event THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today […]
